



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/026,106	12/21/2001	Jean-Christophe Renault	LUD-5752 DIV JEL/NDH (101)

24972  
FULBRIGHT & JAWORSKI, LLP  
666 FIFTH AVE  
NEW YORK, NY 10103-3198

CONFIRMATION NO. 7513

## FORMALITIES LETTER



\*OC000000008569176\*

Date Mailed: 08/05/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY

DOCKET DEPT.  
RECEIVED  
2002 AUG 13 A 10:32  
FULBRIGHT & JAWORSKI, LLP  
NEW YORK OFFICE



VIA FIRST CLASS MAIL

I hereby certify that this correspondence is being deposited with the U.S. Postal Service via first class mail in an envelope addressed to the U.S. PTO, Box: Sequence, P.O. Box 2327, Arlington, VA 22202 on August 16, 2002.

Fulbright & Jaworski L.L.P.

*Lance Olds*

LUD 5752 DIV JEL/NDH (10109097)

# 1)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) : Jean-Christophe Renault, et al.  
Serial No : 10/026,106  
Filed : December 21, 2001  
For : ISOLATED CYTOKINE RECEPTOR LICR-2  
Art Unit : UNKNOWN  
Examiner : UNKNOWN

August 16, 2002

U.S. Patent and Trademark Office  
Box: Sequence  
P.O. Box 2327  
Arlington, VA 22202

**RESPONSE TO  
SEQUENCE LETTER**

S I R:

Responsive to the letter dated August 5, 2002, a copy of which is attached, please replace the current paper copy and computer readable forms of sequence information with the attached.

The undersigned hereby declares that, to the best of his knowledge, the paper copy and computer readable forms of sequence information are identical to each other and to information set forth in the application as filed. No new matter is believed presented.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.

*Norman D. Hanson*  
Norman D. Hanson, Esq.  
Registration No. 30,946

666 Fifth Avenue  
New York, New York 10103-3198

25198319.1